VM26 therapy in children with drug-refractory lymphocytic leukemia

Gaston Rivera, Gary V. Dahl, Sharon B. Murphy, W. P. Bowman, R. J. Aur, Thomas, L. Avery, J. V. Simone

Research output: Contribution to journalArticlepeer-review


The information from these trials should aid in the design of future treatment strategies for leukemia patients at high risk of early relapse. Since VM26 in combination chemotherapy effectively destroyed populations of leukemia cells not susceptible to the cytotoxic activity of conventional agents, its most important future role may be in alternate remission induction treatments or perhaps as an added component of primary treatments.

Original languageEnglish
Pages (from-to)169-172
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Issue number2-3
StatePublished - Apr 1982


Dive into the research topics of 'VM26 therapy in children with drug-refractory lymphocytic leukemia'. Together they form a unique fingerprint.

Cite this